The Pharmaletter
One To Watch
Aprea Therapeutics
A biopharmaceutical company headquartered in Boston, Massachusetts, with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics to reactivate the mutant tumor suppressor protein p53, the most commonly mutated gene in cancer.
The Karolinska Development portfolio company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.
In December 2020, Aprea announced the failure of a Phase III trial of eprenetapopt in TP53 mutant myelodysplastic syndromes.
Latest Aprea Therapeutics News
6 June 2022
13 August 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze